Early hepatitis B viral DNA clearance predicts treatment response at week 96
| Autor: | Ji-Long Gu, De-Hui Li, Lang-Qiu He, Zheng-Yuan Fu, Yun-Zhu Long, Cui-Mei Liu, Yuan-Lin Xie, Shifang Peng, Deming Tan, Xiaoyu Fu, Xiao-Ping Xu, Huan-Yu Gong, Si-Hai Li, Zhong-Tian Peng, Xiao-Xuan Hu, Lian-Hui Yao, Bin Gu, Bin Chen, Li-Hua Hu |
|---|---|
| Rok vydání: | 2016 |
| Předmět: |
Male
Time Factors Clinical Trials Study medicine.disease_cause Gastroenterology Chronic hepatitis B 0302 clinical medicine Telbivudine Hepatitis B antigens Hepatitis B e Antigens Prospective Studies Hepatitis B virus DNA Lamivudine General Medicine Entecavir Hepatitis B Middle Aged Viral Load Nucleoside analogue Treatment Outcome HBeAg 030220 oncology & carcinogenesis Area Under Curve 030211 gastroenterology & hepatology Female Viral load medicine.drug Adult medicine.medical_specialty China Hepatitis B virus Guanine Organophosphonates Antiviral Agents 03 medical and health sciences Hepatitis B Chronic Predictive Value of Tests Internal medicine medicine Humans Viral DNA load Hepatitis business.industry Adenine medicine.disease Virology Hepatitis B antibodies ROC Curve DNA Viral business Thymidine |
| Zdroj: | World Journal of Gastroenterology |
| ISSN: | 2219-2840 |
| Popis: | AIM To investigate whether hepatitis viral DNA load at 24 wk of treatment predicts response at 96 wk in patients with chronic hepatitis B. METHODS A total of 172 hepatitis B envelope antigen (HBeAg)-positive chronic hepatitis B patients who received initial treatment at 16 tertiary hospitals in Hunan Province, China were enrolled in this study. All patients received conventional doses of lamivudine and adefovir dipivoxil, telbivudine, entecavir dispersible tablets, or entecavir tablets for 96 wk. Patients who used other antiviral drugs or antitumor and immune regulation therapy were excluded. Patients were stratified into three groups according to their viral DNA load at 24 wk: < 10 IU/mL (group 1), 10-103 IU/mL (group 2), and > 103 IU/mL (group 3). Correlations of 24-wk DNA load with HBeAg negative status and HBeAg seroconversion at 96 wk were analyzed. Receiver operating characteristic curve analysis was used to test the predictive value of the HBV DNA load at 24 wk for long-term response. RESULTS The rates of conversion to HBeAg negative status and HBeAg seroconversion rates were 53.7% and 51.9%, respectively, in group 1; 35.21% and 32.39% in group 2; and 6.38% and 6.38% in group 3. The receiver operating characteristic curves for the three subgroups revealed that the lowest DNA load (< 10 IU/mL) was better correlated with response at 96 wk than a higher DNA load (10-103 IU/mL). Nested PCR was used for amplifying and sequencing viral DNA in patients with a viral DNA load > 200 IU/mL at 96 wk; resistance mutations involving different loci were present in 26 patients, and three of these patients had a viral DNA load 10-103 IU/mL at 96 wk. CONCLUSION Hepatitis B viral DNA load at 24 wk of antiviral treatment in patients with chronic hepatitis B is a predictor of the viral load and response rate at 96 wk. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|